^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Telomerase inhibitor

    Related drugs:
    9d
    NRG-GI007: Phase I study of OBP-301, an oncolytic virus, and definitive chemoradiation in locally advanced esophageal cancer. (PubMed, Int J Radiat Oncol Biol Phys)
    OBP-301 administration before and during CRT is feasible and safe, resulting in a very promising cCR rate. A randomized study is being planned to further evaluate safety and efficacy.
    P1 data • Journal
    |
    TERT (Telomerase Reverse Transcriptase)
    |
    carboplatin • paclitaxel • Telomelysin (suratadenoturev)
    15d
    HARNESS-1: A Study of the Safety, Pharmacokinetics and Exploratory Efficacy ofnRC220 in Combination with Osimertinib in Adult Patients with Non-nSmall Cell Lung Cancer. (ACTRN12626000325303)
    P1, N=40, Recruiting, Racura Oncology Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • Zantrene (bisantrene)
    1m
    THIO-101: THIO Sequenced With Cemiplimab in Advanced NSCLC (clinicaltrials.gov)
    P2, N=227, Active, not recruiting, Maia Biotechnology | Recruiting --> Active, not recruiting
    Enrollment closed • IO biomarker
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Libtayo (cemiplimab-rwlc) • ateganosine (THIO)
    1m
    GV1001, hTERT Peptide Fragment, Prevents 5-Fluorouracil-Induced Mucositis by Inhibiting Mitochondrial Damages. (PubMed, Cells)
    GV1001 markedly mitigated these 5-FU-induced mitochondrial defects. Taken together, GV1001 mitigates CIM by most likely preserving mitochondrial integrity and function, supporting its potential as a strategy to prevent cancer chemotherapy-associated mucosal injury in patients.
    Journal
    |
    TERT (Telomerase Reverse Transcriptase)
    |
    5-fluorouracil • LucaVax (tertomotide)
    2ms
    Evaluating Outcomes in Acute Promyelocytic Leukemia Patients Treated with All-Trans-Retinoic Acid and Arsenic Trioxide. (PubMed, Indian J Hematol Blood Transfus)
    Acute promyelocytic leukemia (APML) is characterized by promyelocytic leukemia retinoic acid receptor alpha (PML-RARA) fusion gene resulting from at (15;17) translocation. While, TLC significantly decreased from baseline in high risk cases to last follow-up (24 × 109/L vs. 9 × 109/L; P = 0.016). Patients with APML can be successfully treated with a combination of ATO and ATRA.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • RARA (Retinoic Acid Receptor Alpha) • CD33 (CD33 Molecule) • PML (Promyelocytic Leukemia) • ANPEP (Alanyl Aminopeptidase, Membrane)
    |
    Vesanoid (tretinoin) • arsenic trioxide
    2ms
    Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    SF3B1 (Splicing Factor 3b Subunit 1)
    |
    SF3B1 mutation
    |
    Rytelo (imetelstat)
    2ms
    Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma (clinicaltrials.gov)
    P2, N=27, Recruiting, Weill Medical College of Cornell University | Trial completion date: Apr 2028 --> Apr 2030 | Trial primary completion date: Apr 2026 --> Apr 2028
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Telomelysin (suratadenoturev)
    2ms
    A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy (clinicaltrials.gov)
    P1, N=36, Recruiting, Children's Oncology Group | Trial completion date: Jun 2026 --> Mar 2028 | Trial primary completion date: Jun 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    NF1 (Neurofibromin 1) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11)
    |
    RAS mutation • CBL mutation
    |
    cytarabine • methotrexate • leucovorin calcium • fludarabine IV • Rytelo (imetelstat) • Starasid (cytarabine ocfosfate)
    2ms
    GV1001 Reprograms CD47 Immune Checkpoint to Restore Macrophage Antitumor Activity in Oral Squamous Cell Carcinoma. (PubMed, Int J Mol Sci)
    GV1001 administered alone or in combination with cisplatin produced antitumor effects. Collectively, these findings demonstrate that GV1001 functions as a potent immunomodulatory anticancer peptide that downregulates CD47 expression and restores macrophage-mediated tumor clearance, highlighting its potential as a therapeutic strategy for OSCC.
    Journal
    |
    TERT (Telomerase Reverse Transcriptase) • CD47 (CD47 Molecule)
    |
    cisplatin • LucaVax (tertomotide)
    3ms
    QUATRO-APL: Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia (clinicaltrials.gov)
    P3, N=150, Recruiting, Quetzal Therapeutics
    New P3 trial
    |
    PML (Promyelocytic Leukemia)
    |
    Chr t(15;17)
    |
    Vesanoid (tretinoin) • arsenic trioxide
    3ms
    P53-armed Oncolytic Adenovirus Enhances the Efficacy of PD-1 Blockade in Neuroblastoma by Inducing Immunogenic Cell Death. (PubMed, Anticancer Res)
    OBP-702 is a promising antitumor strategy to promote the antitumor effect of ICIs by inducing ICD against NB tumors.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • HMGB1 (High Mobility Group Box 1)
    |
    PD-L1 expression • MYCN amplification
    |
    Telomelysin (suratadenoturev) • pfifteloxin (OBP-702)
    3ms
    HARNESS-1: A Study of the Safety, Pharmacokinetics and Exploratory Efficacy ofnRC220 in Combination with Osimertinib in Adult Patients with Non-nSmall Cell Lung Cancer. (ACTRN12626000325303)
    P1, N=40, Not yet recruiting, Racura Oncology Ltd.
    New P1 trial
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • Zantrene (bisantrene)